Methods and compositions for targeting compounds to muscle

• US 6,329,501 B1
• Filed: 05/26/1998
• Issued: 12/11/2001
• Est. Priority Date: 05/29/1997
• Status: Expired due to Fees

• Current Assignee: Auburn University
• Original Assignee: Auburn University
• Inventors: Samoilova, Tatiana, Smith, Bruce F.
• Primary Examiner(s): Carlson, Karen Cochrane
• Application Number:
  US09/084,605
• Time in Patent Office: 1,295 Days
• Field of Search: 530/300.358, 530/387.1, 530/388.1, 435/7.1, 424/93.6
• US Class Current: 530/329
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4708 Duchenne dystrophy
• CPC Class Codes: C07K 14/4716 Muscle proteins, e.g. myosin, actin
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• CPC Class Codes: G01N 2800/2878 Muscular dystrophy
• CPC Class Codes: G01N 2800/2885 Duchenne dystrophy
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue

Abstract

Compositions for use in targeting therapies to muscle cells are provided. The compositions comprise peptides which are capable of binding muscle cells in vivo.

Claims

1. An isolated peptide, wherein said peptide is 7 amino acids to 20 amino acids, comprising an amino acid sequence selected from the group consisting of:

SEQ ID NO;

1, SEQ ID NO;

2, SEQ ID NO;

3, SEQ ID NO;

4, SEQ ID NO;

5, SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

9, SEQ ID NO;

10, SEQ ID NO;

11, SEQ ID NO;

12, SEQ ID NO;

13, SEQ ID NO;

14, SEQ ID NO;

15, SEQ ID NO;

16, SEQ ID NO;

17, SEQ ID NO;

18, SEQ ID NO;

19, SEQ ID NO;

20, SEQ ID NO;

21, SEQ ID NO;

22, SEQ ID NO;

23, SEQ ID NO;

24, SEQ ID NO;

25, SEQ ID NO;

26, SEQ ID NO;

27, SEQ ID NO;

28, and SEQ ID NO;

29.

2. The peptide of claim 1, wherein said peptide is capable of binding muscle cells in vivo.

3. The peptide of claim 2, wherein said peptide is a muscle-type specific peptide.

4. The peptide of claim 3, said muscle-type specific peptide comprising an amino acid sequence selected from the group consisting of:

SEQ ID NO;

1, SEQ ID NO;

2, SEQ ID NO;

3, SEQ ID NO;

4, SEQ ID NO;

5, SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

9, SEQ ID NO;

10, SEQ ID NO;

11, SEQ ID NO;

12, SEQ ID NO;

13, SEQ ID NO;

14, SEQ ID NO;

15, SEQ ID NO;

16, SEQ ID NO;

17, SEQ ID NO;

18, SEQ ID NO;

19, SEQ ID NO;

20, SEQ ID NO;

21, SEQ ID NO;

22, SEQ ID NO;

23, SEQ ID NO;

24, SEQ ID NO;

25, SEQ ID NO;

26, SEQ ID NO;

27, and SEQ ID NO;

28.

5. The peptide of claim 3, wherein said peptide is capable of binding specific muscle cells selected from the group consisting of smooth, skeletal, and cardiac muscle cells.

6. The peptide of claim 3, wherein said peptide is a species specific peptide.

7. The peptide of claim 3, wherein said peptide is a species independent peptide.